Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma

Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma

Abstract Background and Aim We evaluated the efficacy of rechallenge transcatheter arterial chemoembolization (TACE) after lenvatinib (LEN) treatment in patients with previous TACE failure/refractoriness. Methods We enrolled 63 consecutive patients with a history of TACE failure/refractoriness prior...

Full description

Bibliographic Details
Main Authors: Sawako Uchida‐Kobayashi, Ken Kageyama, Shigekazu Takemura, Kazuhiro Matsumoto, Naoshi Odagiri, Atsushi Jogo, Kohei Kotani, Ritsuzo Kozuka, Hiroyuki Motoyama, Etsushi Kawamura, Atsushi Hagihara, Akira Yamamoto, Hideki Fujii, Shogo Tanaka, Masaru Enomoto, Akihiro Tamori, Yukio Miki, Shoji Kubo, Norifumi Kawada
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:JGH Open
Subjects:
hepatocellular carcinoma
intolerance
lenvatinib
molecular‐targeted agents
refractoriness
transcatheter arterial chemoembolization
Online Access:https://doi.org/10.1002/jgh3.12819

Internet

https://doi.org/10.1002/jgh3.12819

Similar Items